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Abstract: 
Multi Drug Resistance (MDR) is one of the major causes of chemotherapy failure in human malignancies. Curcumin, the active 
constituent of Curcuma longa is a proven anticancer agent potentially modulating the expression and function of these MDR 
proteins. In this study, we attempted to test curcumin for its potential to inhibit the expression and function of multidrug resistance 
associated protein 1 (MRP1) in retinoblastoma (RB) cell lines through western blot, RT-PCR and functional assays. In silico analysis 
were also performed to understand the molecular interactions conferred by curucmin on MRP1 in RB cells. Western blot and RT-
PCR analysis did not show any correlation of MRP1 expression with increase in concentration of curcumin. However, inhibitory 
effect of curcumin on MRP1 function was observed as a decrease in the efflux of fluorescent substrate. Moreover, Curcumin did not 
affect 8-azido-ATP-biotin binding to MRP1 and it also showed inhibition of ATP-hydrolysis stimulated by quercetin, which is 
indicative of curcumin’s interaction with the substrate binding site of MRP1. Furthermore, homology modelling and docking 
simulation studies of MRP1 also provided deeper insights into the molecular interactions, thereby inferring the potential binding 
mode of curcumin into the substrate binding site of MRP1. 
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Background: 
Retinoblastoma (RB) is the most common primary intraocular 
malignancy of children [1]. Chemotherapy is the treatment of 
choice following enucleation in patients with optic nerve and 
choroids invasion and also orbital extension [2]. One of the 
major problems related with chemotherapy drugs in RB is 
resistance against anticancer agents [3]. Over-expression of P-
glycoprotein (P-gp), Multidrug Resistance-associated Protein 1 
(MRP1), and Lung Resistance-related Protein (LRP) are 
associated with development of multi drug resistance (MDR) in 
various cancer cells [4]. MRP belongs to the ATP-binding 
cassette (ABC) transporter family [1]. The MRP family consists  
of nine members (MRP1-9), all these proteins contain 
hydrophobic membrane spanning domains (TMDs) and 
cytoplasmic nucleotide-binding domains (NBDs), wherein, 
NBD is responsible for ATP binding/hydrolysis [5]. Earlier 
studies have reported that MRP1 expression is associated with 
the rare failure of chemotherapy in RB tumor despite the use of 
cyclosporine  [6]. It was also reported that cells which highly 
express MRP1 show resistance to anti-cancer drugs like vinca 
alkaloids, anthracyclines and epipodophyllotoxins 
[7].Chemotherapeutic treatments have been associated with 
adverse side effects and dose limiting toxicity [8]. Many natural 
compounds have been reported to interact with the 
transmembrane transporters and also found to sensitize cancer 
cells to anti-cancer drugs [9]. In the recent decades, extensive BIOINFORMATION  open access 
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research has been done on curcumin to establish its biological 
and pharmacological activities. It has been reported that 
curcumin confers therapeutic and chemo-sensitization effect, 
a n d  a l so  r e p o r te d  t o  h a v e  m od u l a t i n g  ro l e  o n  M D R  p r o t e i n s  
[10]. These findings suggest the curcumin`s interaction with the 
conserved functional domains of the drug resistance proteins, 
thereby inhibiting their function. However, the molecular 
mechanism behind the physiological effects of curcumin is not 
well-studied. Hence, in this present study, we have selected Y79 
RB cells as an in vitro model for RB cancer and studied the effect 
of curcumin on MRP1 expression and function. Further in silico 
approaches have also been studied to deduce the inhibitory 
binding mode of curcumin on MRP1 protein.  
 
Methodology: 
Reagents 
Curcumin (Sigma) were dissolved in dimethyl sulphoxide 
(DMSO) and stored at -200c. Cell culture materials were 
purchased from Invitrogen (Carlsbad, CA, USA). All other 
chemicals and reagents were of the highest grade commercially 
available. 
 
Cell culture:  
The Y79 cell line was obtained from the American Type Culture 
Collection (Manassas, VA, USA) and maintained in a RPMI-
1640 medium supplemented with 20% fetal bovine serum with 
50ng/mL of streptomycin and 1.25ng/mL of Amphotericin B at 
370c in a humidified atmosphere with 95% O2 and 5% CO2.  
 
Effects of curcumin on MRP1 expression in RB cell line 
RT-PCR studies for MRP1 on curcumin treated (2-10µM) & 
untreated Y79 RB cells were performed with 2µg of total RNA 
from each sample. The cDNA products were amplified for 35 
cycles using specific primers and the amplification product was 
fractionated by electrophoresis using 2% agarose gel containing 
0.5% Ethidium Bromide (Table 1, see supplementary material). 
Further, for protein expression studies, the curcumin treated 
and untreated cell lysates (50µg) were loaded onto 8% 
polyacrylamide gels and the western blot for MRP1 (1:2000) and 
β-actin (1:4000) was performed. Protein bands were visualized 
using a chemiluminescence kit. The relative amount of MRP1 
mRNA and protein expression was determined by 
densitometer. 
 
MRP1 functional study using calcein-AM by flow cytometry 
The accumulation of calcein-AM, which is a fluorescent 
substrate for MRP1, was used for the functional study.  5x104 
Y79 cells were collected and 0.5µM of calcein-AM was added in 
the presence and absence of 10µM curcumin and incubated at 
370c in the dark for 30 minutes. Similarly, the inhibitors of 
MRP1 (1mM probenecid and 100µM indomethacin) was added 
and the accumulation of calcein was measured. After the 
incubation period, the cells were pelleted by centrifugation at 
5000rpm for five minutes. To the pellet, 500µl of PBS containing 
0.1% BSA was added and analysed immediately by flow 
cytometry. 
 
ATPase activity of MRP1 
ATPase activity of MRP1 in Y79 RB cells was measured by the 
end point Pi release assay. 100µg/ml concentration of protein 
was incubated 2.5mM sodium fluoride and 0.2mM beryllium 
sulfate for 5 minutes at 370C. Following incubation, different 
concentration of curcumin in the presence and absence of 
quercetin (10µM) was added and incubated for 3 minutes at 
370C. The reaction was initiated by the addition of 5mM ATP 
and terminated with 2.5% concentration of SDS after 20 minutes 
of incubation. The amount of Pi released was quantified using 
colorimetric method. MRP1-specific activity was recorded as 
the BeFx-sensitive ATPase activity.  
 
Photoaffinity labelling of MRP1 with 8-azido-ATP-bitoin 
Crude membranes of MRP1 expressing Y79 RB cells (100µg 
protein) were incubated with 5mM Mgcl2 and 100µM 8-azido-
ATP-biotin in the dark on ice for 5 min in the presence and 
absence of 10µM curcumin. The mixture was photolinked using 
UV light for 10 minutes. Immunoprecipitation of the 
photolinked sample was performed using MRP1 monoclonal 
antibody linked to protein A immobilized on agarose. Further, 
the immunoprecipitated protein was blotted and visualized 
with streptavidin horseradish peroxidase. 
 
Statistical analysis 
All experimental data were expressed as the mean ± Standard 
Deviation (SD) from triplicate samples of three independent 
experiments. Statistical analyses were performed by one-way 
analysis of variance (ANOVA) using SPSS 11.0 software. Values 
of p<0.05 were considered statistically significant.  
 
In silico Analysis 
Three dimensional structure of MRP1 have not been elucidated 
yet. Hence, homology search was performed for MRP1 amino 
acid sequence (UniProt ID: P33527) using BLASTp against 
Protein Data Bank (PDB) to identify the suitable templates 
towards modelling of MRP1 structure. Homology search results 
revealed that homodimeric multidrug exporter Sav1866 (PDB 
ID: 2HYD) of Staphylococcus aureus [11] as a suitable template, 
as it shared an overall sequence identity of 28% and similarity 
of 49% with MRP1. Further, for generating the homology model 
of MRP1, sequence alignment with Sav1866 was produced 
using ClustalW2 with default parameters. Further, based on 
this alignment, the three dimensional structure of MRP1 was 
generated using Modeller9v8 [12]. Among the 100 decoys 
generated for MRP1, the one with significant molecular 
Probability Density Function (PDF) and Discrete Optimized 
Potential Energy (DOPE) [13] was subjected to refinement. 
Further, the modelled structure was energy optimized through 
GROMACS 4.3.1, molecular dynamics package [14, 15]. The 
optimized model was evaluated for the stereo chemical aspects 
using PROCHECK [16] and for the energy profile using ProSA 
II server [17]. The structural quality of the protein was further 
evaluated by comparing the topology of the protein through 
structural superposition. The more sensitive TM-score was 
generated using TM align to check the probability of proteins 
sharing the same fold at the structural level. TM-Score > 0.17 is 
suggestive of a model and template sharing the similar 
topology [18]. 
 
The possible ligand binding cavities within the generated 
model was predicted using castP server [19]. The structural co-
ordinates of curcumin (ACD0022) was retrieved from Indian 
Plant Anticancer Compound Database [20]  and  geometry 
optimized using PRODRG2 sever [21]. 
Molecular Docking simulation was carried out using AutoDock 
4.2. Initially, the energy optimized protein and the ligand were BIOINFORMATION  open access 
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prepared for docking by adding polar hydrogens. Further, the 
protein and the ligand were also optimized by adding Kollman 
united atom charges and Gasteiger charges, respectively. 
Flexibility of the ligand was assigned based on its torsional 
degrees of freedom through Autotors, with the protein fixed to 
rigid throughout the process of docking simulation  [22, 23]. 
Grid box covering the complete binding cavity as predicted 
using CASTp for MRP1 (104×104×104; 0.667Ǻ) was built and 
the same was used for docking process. Further, Grid maps 
were generated for each atom within the ligand of MRP1 using 
Autogrid. Docking calculation was performed using 
Lamarckian genetic algorithm with default parameters, except 
for the number of GA runs which was set to 100. Further, 
cluster analysis was performed with a threshold RMSD set to 
2.0Ǻ to find the optimal binding orientation of the ligands. 
Potential binding pose of curcumin with MRP1 was predicted 
based on the binding energy and inhibitory constant. Finally, 
bonded and non-bonded interactions were also analyzed and 
visualized using PyMOL  [24]. All the major structural 
bioinformatics tools used in this study were run on Open 
Discovery Linux platform [25] installed in Dell Precision 
workstation. 
 
 
Figure 1: Effect of curcumin on MRP1 mRNA and protein 
expression in RB cell line: Dose-dependent effect of curcumin 
(2, 5, 10µM) after 72hrs on the MRP1 mRNA and protein 
expression in Y79 RB cells. (A) MRP1 and GAPDH expression 
in the Y79 RB cells. (B) MRP1 and beta actin expression in RB 
cells. Lane 1: Control cells, Lane 2: 2µM curcumin, Lane 3: 5µM 
curcumin, Lane 4: 10µM curcumin and Lane 5: Molecular 
weight marker. Both mRNA and protein level of MRP1 in 
curcumin treated was similar to the DMSO treated control, 
indicating that curcumin did not affect the expression level of 
MRP1. 
 
Results:  
Effect of curcumin on MRP1 expression in RB cell line  
The Y79 RB cells treated with different concentrations of 
curcumin (2, 5 and 10µM) for 72 hours were detected by RT-
PCR and western blot. It was found that the mRNA and protein 
level of MRP1 was similar to that of DMSO treated control RB 
cells, indicating absence of curcumin’s effect on MRP1 
expression (Figure 1A&B).    
 
Figure 2: MRP1 functional activity in the Y79 RB cells: (2A) 
Effect of curcumin on MRP1 function was assessed by 
measuring the accumulation of fluorescent substrate calcein-
AM. Histogram showing peak in pink color represents 
(unstained cells), green color (control cells) and blue color 
represents (10µM curcumin treated cells). (2B) Calcein 
accumulation is shown as bar diagram for n=3 experiments and 
are expressed as the mean ± S.D. * p<0.05, significantly different 
from the control. 
 
 
Figure 3: Effect of MRP1 inhibitors on calcein accumulation in 
Y79 RB cells: Y79 cells were incubated with and without 
inhibitors (100µM indomethacin and 1mM probenecid) and the 
calcein accumulation was observed at different time intervals. 
Data are expressed as the mean ±S.D for n=3 experiments.* 
p<0.05 significantly different from the control. 
 
Effect of curcumin on MRP1 function by flow cytometry 
The effect of curcumin on the MRP1 transport was tested by the 
accumulation of the fluorescent substrate calcein-AM using 
flow cytomtery. The Y79 cells were incubated with calcein-AM 
and the intensity of fluorescence substrate accumulated was 
measured by FACS. Accumulation of fluorescent substrate was 
found to be increased (to nearly 50%) in the curcumin treated 
cells, when compared with the controls (Figure 2A and B). 
Similarly, indomethacin and probenecid (MRP1 inhibitors) BIOINFORMATION  open access 
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caused a significant increase in calcein accumulation at different 
time intervals in Y79 cell lines, which shows the involvement of  
MRP1 calcein efflux [Figure 3], and the results were also found 
to be statistically significant with p<0.05.  
 
 
Figure 4: Effect of curcumin on basal and quercetin stimulated 
ATPase activity and photoaffinity labeling of MRP1 with 8-
azido-ATP-biotin: (4A) Y79 cells expressing MRP1 (100µg of 
protein/ml) were incubated with increasing concentration of 
curcumin in the presence and absence of quercetin in the 
ATPase assay buffer. The reaction was initiated by the addition 
of 5mM ATP and terminated with 2.5% concentration of SDS 
after 20 minutes of incubation; the amount of Pi released was 
quantitated by colorimeter. (●) MRP1 basal activity; and (■) 
quercetin-stimulated MRP1 ATPase activity in the presence of 
different concentration of curcumin. Value represents ±SE from 
at least three independent experiments. (4B) Crude membranes 
of (100µg protein) were incubated with 100µM 8-azido-ATP-
biotin in the dark on ice for 5 min in the presence and absence 
of 10µM curcumin. The proteins were then immunoprecipitated 
with MRP1 antibody linked to agarose protein A beads. The 
immunoprecipitated protein was blotted and visualized with 
streptavidin horseradish peroxidase. The addition of 10mM 
ATP prevented photlabeling. Lane 1: 8-azido-ATP-bitoin, Lane 
2: 10µM curcumin and Lane 3: 10mM ATP. 
 
Effect of curcumin on ATPase activity of MRP1 
A T P a s e  a c t i v i t y  o f  M R P 1  i n  t h e  p r e s e n c e  o f  c u r c u m i n  w a s  
studied to assess the effect of curcumin on this transporter. Our 
results show that curcumin was able to stimulate the basal 
ATPase activity of MRP1 at very low concentration, but 
inhibited the activity at higher concentration. This is indicative 
of curcumin’s direct interaction with the MRP1. Moreover, we 
also observed the inhibition of quercetin stimulated ATP 
hydrolysis by MRP1, mediated by curcumin in Y79 RB cell lines 
[Figure 4A].  
 
Effect of curcumin on photoaffinity labelling of MRP1 by 8-
azido-ATP-biotin 
To determine the interaction sites of MRP1 with curcumin, 
photoaffinity labelling of MRP1 was performed using 8-azido-
ATP-biotin. Curcumin had no effect on 8-azido-ATP-biotin of 
MRP1 at 10µM concentration in Y79 RB cell line. The cross 
linking of 8-azido-ATP was inhibited in the presence of 10mM 
ATP. This suggests that curcumin produce their effect most 
likely by interacting at the substrate binding sites rather than at 
the nucleotide-binding sites of the MRP1 protein [Figure 4B].   
 
 
Figure 5: Homology based three dimensional model of MRP1. 
 
Homology Modeling of MRP1 
Among the experimentally determined structures of ABC 
transporter super family, SAV1866 (PDBID: 2HYD) of 
Staphylococcus aureus was found to be an appropriate template 
for human MRP1 with optimal query coverage (300-1531). Thus, 
three dimensional structure of human MRP1 was generated 
based on the molecular modeling protocol implemented by M. 
K. DeGorter et al [26].The generated structural co-ordinates of 
human MRP1 was geometry optimized  with a potential energy 
of -1.6761530e+05 kJ/mol. The resultant 3D structure of human 
MRP1 is predominantly helical in TM domains and β-sheets in 
the NBDs (Figure 5A). The overall stereo chemical aspects of 
MRP1 were inspected through Ramchandran plot, in which 
9 1 . 0 %  o f  t h e  r e s i d u e s  i n  t h e  m o s t  f a v o u r e d  r e g i o n  w i t h  n o  
residues in disallowed region. Moreover, the overall quality of 
the model was further ascertained to be good with a Z-score of -
6.02 as calculated using ProSA. TM-score of 0.93037 was 
calculated using the more sensitive structural alignment 
algorithm, TM-align. This score was suggestive of the generated 
model to share the same topology of the template with high 
probability. Hence, the model validated at the geometrical and 
energetic aspects ensure the plausibility for future analysis. 
 
Binding cavity analysis 
Binding site residues of MRP1 were predicted using CASTp 
(Table. 2 see supplementary material). The binding cavity of 
volume and area with 25694 and 9954.7, respectively were 
considered for the study. The amino acids residing in this cavity 
were documented to be involved in binding and transport of 
substrates [27].  
 
Molecular Docking of MRP1 with curcumin and ATP 
Molecular docking studies were performed for the optimized 
three dimensional structure of MRP1 with curcumin using 
LGA, to infer its binding mode. Among the conformers BIOINFORMATION  open access 
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generated, potential pose with lowest binding energy and 
highest binding affinity was selected for analysis. Curcumin 
showed bonded and non-bonded interactions with the substrate 
binding site of MRP1 with the binding energy and inhibitory 
constant of -7.39 kJ/mol and 3.82µM, respectively. Further, 
interaction analysis of MRP1 with curcumin showed hydrogen 
bonding interactions Tyr384, Gln450 and Arg1249 and non 
bonded interactions with Tyr324, Phe385, Met443, Ser446, 
Ala447, Ile598, Val1194, Trp1198, Val1248 and Ser1252 (Figure 
6A) (Table 3,  see supplementary material). 
 
 
Figure 6: Molecular interaction observed between MRP1 with 
Curcumin. Binding site residues (RED) of MRP1 and Curcumin 
(Yellow) represented in sticks. The bonded and non- bonded 
interactions are visualized through PyMOL with H-bonded 
interaction represented through yellow color dashed lines. 
 
Discussion: 
Curcumin is a polyphenolic compound derived from turmeric. 
Its ability to affect gene transcription and induce apoptosis in 
various animal models with particular relevance to cancer 
chemoprevention and chemotherapy patients is well 
documented [10]. It has been studied that curcumin also serve 
as inhibitors of ABC transporters [28].  Recent studies have 
shown that curcumin significantly lowered the MDR1 gene 
expression in KB-V1 cervical carcinoma cell line. Similarly, it 
increased the accumulation of Rhodamine 123 and inhibited it’s 
efflux in cells which over-express P-glycoprotein [29]. In the 
present study, we investigated the effect of curcumin on MRP1 
expression and function in Y79 RB cells.  
 
In our earlier study, we have performed MTT assay to 
determine the relative cytotoxicity of curcumin in the Y79 RB 
cell line (data not shown;  [30]). The concentrations that were 
less toxic to cells were chosen for further experiments. When 2-
10µM curcumin was added to the Y79 for 72 hours, no effect 
was observed on MRP1 mRNA and protein expression. Similar 
results were observed by Wanida et al, where no change in the 
expression of MRP1 was observed after curcumin treatment in 
HEK-293 cells [31]. Cellular accumulation and the efflux studies 
were performed in Y79 RB cells employing calcein-AM as 
substrate for MRP1. This substrate is a non-fluorescent and 
lipophilic acetoxymethyl ester of calcein that rapidly diffuses 
through the plasma membrane into cells.  In the cytosol, 
calcein-AM is metabolized by esterase to calcein which is 
effluxed by the MRP1 protein. In a previous study, curcumin 
was also found to inhibit MRP1 transport by increasing the 
accumulation of fluorescent substrate calcein-AM and fluo4-
AM using flow cytometry HEK-293 cells [31]. In the present 
study, we also found that there was a 30% increase in the 
accumulation of fluorescent substrate calcein-AM on curcumin 
treated Y79 cells by flow cytometry analysis. Similarly, 
indomethacin and probenecid (MRP1 inhibitors) caused a 
significant increase in calcein accumulation at different time 
intervals in Y79 cell lines, which show that MRP1 is involved in 
the efflux of calcein. Exposure to drug substrates can lead to 
stimulation or inhibition of ATPase activity of the ABC 
transporters [32]. Similar to P-gp [29], we found that curcumin 
was able to stimulate the ATPase activity of MRP1 at low 
concentration, but there was an inhibition of activity at higher 
concentration, which can be attributed to curcumin’s interaction 
with MRP1’s binding site. Further, our results also showed the 
inhibitory activity of curcumin on quercetin stimulated ATP 
hydrolysis by MRP1 in a dose dependent manner. Recently, 
Heleen et al also showed the inhibitory activity of curcumin on 
both MRP1 and MRP2 mediated transport in MDCKII cells, and 
it was also demonstrated that glutathione dependent 
metabolism of curcumin to play an important role in MRP1 
inhibition [9]. To ascertain the probable curcumin interaction 
sites on MRP1, photoaffinity labeling of MRP1 was performed. 
This was done using 8-azido-ATP-biotin, an analog of ATP, 
which has been already to bind specifically to the nucleotide 
binding domain of P-gp and MRP [31]. Subsequently, in the post 
labelling experiments we found the lack of curcumin’s effect on 
8-azido-ATP-biotin binding to MRP1 at 10µM concentration in 
Y79 cell lines. This suggests that curcumin produces its effect 
most likely by interacting at the substrate binding sites rather 
than at the nucleotide-binding sites of the MRP1 protein to 
modulate ATP hydrolysis. 
 
It has been documented through mutational studies that the 
residues spanning (Transmembrane) TM11 (Ile598) and TM17 
(Val1248) are the regions involved in substrate binding and its 
transport. Further, retention in the transport activity was 
observed on mutating Phe385, Trp1198 and Arg1249, which 
signifies the biological importance of these residues on 
substrate transport [25]. In the present study, docking 
interaction analysis of MRP1-curcumin complex showed 
network of bonded and non bonded interactions with 
Curcumin to the amino acid residues residing in the 
documented substrate binding region. Docking studies also 
inferred that oxygen atoms of phenolic and methoxy functional 
groups spanning terminal phenyl rings of curcumin to play a 
crucial role for inhibitory action.  
 
Conclusion:  
Multi-drug resistance in tumour cells is a significant 
impediment to the success of chemotherapy in many cancers. 
Curcumin, a natural polyphenolic compound has led to 
scientific interest in its ability as a chemotherapeutic agent. Our 
in vitro results showed the potential of curcumin in modulating 
the function and expression of multi-drug resistance proteins 
MRP1. Furthermore, in silico molecular docking studies of these 
MDR proteins with curcumin provides an insight on the active 
binding mode of curcumin. Thus, curcumin can be used as a 
promising MDR chemosensitizer in modulating the multidrug 
resistance property in various cancers.  BIOINFORMATION  open access 
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Supplementary material: 
 
Table 1: Table shows the PCR primers used in the gene expression studies 
Gene  Primer sequences (3’-5’)  Annealing temp. 0C PCR  product  size 
MRP1 
FP CGTCTACTCCAACGCTGAC 
RP CTGGACCGCTGACGCCCGTGAC 
570C 325bp 
GAPDH 
FP GCCAAGGTCATCCATGACAAC 
RP GTCCACCACCCTGTTGCTGTA 
 
630C 498bp 
 
Table 2: Binding Cavity predicted through Computed Atlas of Surface Topography of proteins (CASTp) 
Protein 
Area 
(A2) 
Volume 
(A3) 
Residues spanning in the predicted  binding cavity 
MRP1 9954.7 25694 
W309,K319,G322,P323,Y324,F325,M327,S328,F329,F330,F331,K332,A333,I334,
H335,D336,L337,M338,M339,L369,V372,T373,Q377,V380,L381,Y384,F385,C3
88,F389,V390,S391,G392,M393,K396,V424,N425,S428,V429,Q432,R433,F434,
M435,D436,L437,A438,T439,Y440,N442,M443,I444,W445,S446,A447,P448,Q4
50,L453,A454,V479,N480,M483,T487,Q491,H494,M495,K498,R501,I502,R532,
E535,L536,K537,L539,S542,A543,L545,S546,A547,V548,G549,T550,F551,T552,
W553,V554,C555,P557,F558,L559,V560,A561,L562,A587,L588,F589,N590,I591
,L592,R593,F594,P595,L596,N597,I598,L599,P600,M601,V602,I603,S604,S605,I
606,Q608,A609,V611,S612,F982,N985,H986,V987,S988,A989,L990,A991,S992,
N993,Y994,W995,L996,S997,W999,G1032,Y1033,S1034,M1035,A1036,V1037,S
1038,I1039,G1040,G1041,I1042,L1043,S1045,R1046,C1047,L1048,H1049,V1050
,D1051,L1053,H1054,L1057,L1080,V1083,D1084,S1085,M1086,I1087,P1088,E1
089,V1090,I1091,K1092,F1094,M1095,G1096,F1099,N1100,V1101,I1102,G1103,
A1104,V1107,L1110,S1137,R1138,Q1139,L1140,K1141,E1144,S1145,R1148,Y11
52,K1187,Y1190,P1191,I1193,V1194,A1195,R1197,W1198,V1201,R1202,L1203,
E1204,C1205,V1206,G1207,N1208,L1212,V1234,S1235,S1237,L1238,Q1239,T12
41,T1242,Y1243,L1244,N1245,W1246,L1247,V1248,R1249,M1250,S1251,S1252,
E1253, M1254,E1255 and  T1256 
 
 
Table 3: Significant Molecular interactions observed between MRP1 and Curcumin. Residues involved in H-bond interactions were 
bolded. 
Protein 
Predicted 
Binding Energy 
(kJ/mol) 
Inhibitory 
constant 
(Ki) 
Interacting Residues (Bonded and Non bonded contacts) 
MRP1-
Curcumin 
-7.39 3.82µM 
Tyr324,Tyr384,Phe385,Met443,Ser446,Gln450,Ala447,Ile598, 
Val1194,Trp1198,Val1248, Arg1249 and Ser1252 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 